Home > Insider Trading > Filing (0001209191-21-019957)

Filing Details

Accession Number:: 0001209191-21-019957
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-03-11 19:35:16
Reporting Period:: 2021-03-09

Accepted Time:: 2021-03-11 19:35:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1564824	Allakos Inc.	ALLK	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1198325	Daniel Janney	Four Embarcadero Center Suite 2100 San Francisco CA 94111		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-03-09	100	$125.00	103,534	No	4	S	Indirect	By Alta Bioequities L.P.
Common Stock	Disposition	2021-03-11	6,006	$124.62	97,528	No	4	S	Indirect	By Alta Bioequities L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Alta Bioequities L.P.
No	4	S	Indirect	By Alta Bioequities L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	8,519,200	Indirect	See Footnote

Footnotes

Reflects distributions in kind effected by Alta Partners VIII, L.P. ("Alta VIII") and Alta Partners NextGen Fund I, L.P. ("APNG I") subsequent to the Reporting Person's most recent Section 16 report, which distributions were not required to be reported pursuant to Section 16.
Consists of 2,071,147 shares held of record by APNG I and 6,448,053 shares held of record by Alta VII.
The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The Reporting Person is a managing director of Alta Management VIII and, as such, may be deemed to share voting and investment control with respect to the shares held by Alta VIII. The Reporting Person disclaims beneficial ownership of all shares held by Alta VIII, except to the extent of his pecuniary interest therein.
The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC ("APNG I Management"), which is the general partner of APNG I. The Reporting Person is one of three managing directors of APNG I Management and, as such, has voting and investment control with respect to the shares held by APNG I. The Reporting Person disclaims beneficial ownership of all shares held by APNG I, except to the extent of his pecuniary interest therein.
Shares held prior to the reported transaction consisted of an aggregate of 103,634 shares received in pro rata distributions from APNG I and AP VIII subsequent to the Reporting Person's most recent Section 16 report, which distributions were not required to be reported pursuant to Section 16.
Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.25 - $125.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.